For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

The extracellular forms of the IL‐1 cytokines are active through binding to specific receptors
on the surface of target cells. IL‐1 ligands bind to the extracellular portion of their ligand …

Abstract Interleukin 33 (IL-33) is a member of the IL-1 family of cytokines with a growing
number of target cells and a plethora of biological functions. Although it has commonalities …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

The cancer stem cell (CSC) concept has important therapeutic implications, but its
investigation has been hampered both by a lack of consistency in the terms used for these …

Abstract Interleukin-1β (IL-1β) is a master regulator of inflammation. Increased activity of IL-
1β has been implicated in various pathological conditions including myeloproliferative …

For more than 50 years, investigators have considered a malignant stem cell as the potential
origin of and a key therapeutic target for acute myeloid leukemia (AML) and other forms of …

Natural killer (NK) cells are large granular lymphocytes involved in our defense against
certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti …

We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous
leukemia (CML) using a transgenic mouse model. LSC were restricted to cells with long …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …